^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INV322

    i
    Other names: INV322
    Associations

    News

    Trials
    Company:
    Invenra
    Drug class:
    CTLA4 inhibitor, CD25 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    INV322, a TME selective CD25 x CTLA4 bispecific antibody approach for depletion of tumor restricted Tregs (SITC 2022)
    IND-enabling activities are underway with INV322. Ethics Approval All animal studies were reviewed and approved under Invenra's IACUC protocol (I-RP-A-07).
    PD(L)-1 Biomarker • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha)
    |
    CTLA4 expression
    |
    INV322